The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators
Learn how PBPK and QSP modeling support regulatory confidence, accelerate drug development, and align with…
CertaraMay 26, 2026
FDA Rebuilding After DOGE Cuts: Former Regulators Speak Out
Former FDA officials describe the impact of DOGE-era staffing cuts, lost expertise, and the challenges…
CertaraMay 15, 2026
How to Leverage PBPK Modeling and Simulation in Drug Research and Development
Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…
CertaraMay 12, 2026
How Pharma Can Transition to Non-animal Studies for Investigational Drugs
Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…
CertaraMay 5, 2026
From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development
Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…
CertaraApril 28, 2026
ToxStudio® Predictive Toxicology Software
Learn about ToxStudio: Predictive toxicology software to support prediction of drug-induced liver injury (DILI), QT…
CertaraApril 16, 2026
FDA Blueprint Aims To Cut Regulatory Risk for Alternatives to Animal Testing
The FDA’s new draft guidance clarifies how drug developers can validate and use non-animal testing…
CertaraApril 1, 2026
Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations
Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…
CertaraMarch 24, 2026
